4 Gene Therapy Stocks to Watch in 2017
At the halfway mark of 2017, here’s a look at how these four gene therapy companies are performing so far this year.
Your trusted source for investing success
Your trusted source for investing success
At the halfway mark of 2017, here’s a look at how these four gene therapy companies are performing so far this year.
Reports have indicated to the growth for the industry based on the curiosity and need for patients to find new therapies involved to their diseases.
We look at four types of gene editing currently in clinical trials, as well as the pros and cons of each.
Punnett squares and phenotypes, chromatids and codominance: genetics, and all of its associated terms, isn’t the easiest field to understand. And yet experts agree: this is the future of medicine.
By Vivien Diniz
Editas Medicine and Audentes Therapeutics both filed for initial public offerings on January 4, 2016.
